Breast Biopsy Devices Market Size (2024 - 2029)

Breast Biopsy Devices Market Analysis

The Breast Biopsy Devices Market size is estimated at USD 1.23 billion in 2024, and is expected to reach USD 1.58 billion by 2029, growing at a CAGR of 5.12% during the forecast period (2024-2029).

The emergence of the COVID-19 pandemic restrained the breast biopsy devices market. It had a detrimental effect on the market due to the reduction in screening rates for breast cancer, and postponing mammograms, which help doctors determine whether the patient needs a breast biopsy or not, contributed to a delayed diagnosis. These changes in screening rate led to a high number of advanced-stage patients, an increasing mortality rate, and a low supply of diagnostic services. According to the Journal of the American College of Radiology (JACR) report 2023, COVID-19 significantly impacted the breast cancer diagnostic rate. The breast biopsy rate was reduced to 47.3% during the first wave of the pandemic in the United States. The breast biopsies and diagnostic mammography rate was reduced to 47.3% and 57%, respectively, during the first wave of the pandemic in the United States, which hasn’t returned to normal stage like pre-pandemic. Hence, COVID-19 had a negative impact on screening mammography volumes and biopsies rates. However, the breast biopsy devices market is likely to witness growth momentum in coming years owing to the rising burden of breast cancer and growing awareness about early disease diagnosis.

The major factors driving the market are the rising prevalence and awareness of breast cancer and the rising demand for minimally invasive breast biopsy procedures. According to the World Health Organization 2023 report, there are more than 2.3 million cases of breast cancer that occur every year, which makes it the most common cancer among adults. However, nearly 80% of deaths from breast cancer occur in low- and middle-income countries. Breast cancer survival rate has increased to five years after diagnosis and now increased to 80% in most high-income countries, compared with 66% in developing countries like India and just 40% in South Africa. In 95% of countries of the world, breast cancer is the first or second leading cause of female cancer deaths. To control such high incidences and mortality rates due to breast cancer, WHO has launched the Global Breast Cancer Initiative Framework, which gives a road map for all countries to control the prevalence and mortality rate. The main objective of this initiative is to promote early detection and effective management to deliver the full treatment course to at least 80% of diagnosed patients. This initiative will increase the diagnostic rate and treatment rate of breast cancer, which will directly accelerate the breast biopsy devices market. Along with the global initiatives taken by the WHO, there are regional initiatives taken by the European Commission to create awareness about the screening of breast cancer will also have further additional effects on the breast biopsy devices market in that region.

Moreover, the rising demand for minimally invasive breast biopsy procedures will accelerate the market. Minimally invasive biopsy (MIB) has replaced open surgical biopsy in patients with imaging-detected suspicious or indeterminate breast lesions. Compared to surgical excision, MIB has the same or even better precision, decreases the psychological burden affecting the patients, and reduces the costs of treatment. MIB reduces the number of surgical procedures required in patients with impalpable breast cancer compared to diagnostic open surgery. Additionally, the new product launch of MIB accelerates the market. For instance, in February 2022, the FDA approved TeesuVac Breast Biopsy Device Mark 1, a minimally invasive device indicated to obtain percutaneous core biopsy specimens from soft tissue and tumors of the breast, which is developed by TeesuVac ApS, which has expertise in developing biopsy medical devices for more than a decade. Hence, cost-effectiveness and new product launches of minimally invasive breast biopsies will accelerate the breast biopsy devices market.

However, the risk of infections due to the wound formed after biopsy will likely restrain the growth of the breast biopsy devices market's growth rate.

Breast Biopsy Devices Industry Segmentation

As per the scope of the report, breast biopsy refers to a procedure that is used for the removal of tissue from the breast. The procedure is done to identify breast cancer and other kinds of diseases. Different devices, like spring-loaded needles, thin guide wires, and vacuum-assisted devices, are used to perform this procedure effectively. The breast biopsy device market is segmented by product (breast biopsy needles, breast biopsy tables, localization wires, and others), procedure (vacuum-assisted biopsy, core needle biopsy, fine needle aspiration biopsy, liquid biopsy, and surgical biopsy), technique (image-guided biopsy, liquid biopsy), indication (fibroadenoma, suspicious micro-calcifications, complex cyst, recurrent breast cancer, invasive lobular carcinoma, and other indications), end user (breast care centers, hospitals and clinics, and diagnostic centers), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.

The report offers the value (in USD) for the above segments.